Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 2Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 85Neoplasm Metastasis 74Colorectal Neoplasms 74Neoplasms 72Leukemia, Myeloid, Acute 62Breast Neoplasms 54Prostatic Neoplasms 47Multiple Myeloma 47Ovarian Neoplasms 42Pancreatic Neoplasms 41Squamous Cell Carcinoma of Head and Neck 38Melanoma 36Recurrence 33Glioblastoma 33Lung Neoplasms 31Myelodysplastic Syndromes 30Triple Negative Breast Neoplasms 29Lymphoma, Non-Hodgkin 29Advanced Solid Tumors 27Endometrial Neoplasms 26Stomach Neoplasms 24Small Cell Lung Carcinoma 24Carcinoma, Renal Cell 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Brain Neoplasms 22Carcinoma, Hepatocellular 21Sarcoma 19Lymphoma, B-Cell 19Lymphoma, Large B-Cell, Diffuse 18Esophageal Neoplasms 18

Interventions

lorlatinib 1encorafenib 1binimetinib 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hereditary Sensory and Autonomic Neuropathies × 30 days × Clear all
NCT04800822 2026-06-04

PF-07284892 in Participants With Advanced Solid Tumors

Pfizer

Phase 1 Terminated
53 enrolled
CNSGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡